About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
KU Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients with High-Risk Smoldering Multiple Myeloma
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Al-Ola Abdallah
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Al-Ola Abdallah
404 views
August 19, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
20:25
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
21:09
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Hematologic Malignancies
09:31
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox …
Feat.
A. Yacoub
07:15
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation &a…
Feat.
A. Yacoub
09:20
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS &…
Feat.
A. Yacoub
15:41
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inh…
Feat.
T. Lin
12:21
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Ant…
Feat.
T. Lin
10:39
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients…
Feat.
A. Abdallah
06:58
KU Hematology & Medical Oncology Review 2019
KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with…
Feat.
A. Abdallah
05:36
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transpl…
Feat.
A. Abdallah
06:42
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease …
Feat.
A. Abdallah
04:31
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib &…
Feat.
M. Hoffmann
08:34
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutu…
Feat.
M. Hoffmann
12:53
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R…
Feat.
M. Hoffmann
